Continue reading this on our app for a better experience

Open in App
Home Capital Broker's Calls

DBS and OCBC lower respective target prices for CLCT but still deem a 'buy'

The Edge Singapore
The Edge Singapore • 2 min read
DBS and OCBC lower respective target prices for CLCT but still deem a 'buy'
CLCT's Singapore-Hangzhou Science & Technology Park. Photo: CLCT
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

CapitaLand China Trust has suffered from price target cuts following a weaker FY2023 that saw distribution per unit down 10.1% y-o-y.

When calculated in RMB, CLCT reported higher gross revenue and net property income of 5.9% and 10.5% y-o-y respectively.

However, given the weakening RMB vs Singdollar, the reporting currency, CLCT ended FY2023 with a slightly lower revenue that's 2% lower versus FY2022, although net property income was up 2.5% to $117.5 million.

Due to higher interest cost and forex, the REIT reported a lower distributable income of $113.8 million, down 9.4% y-o-y.

Backed by CapitaLand, CLCT owns a portfolio of ten malls, five business parks and logistics parks across 12 cities in China. 

While its retail assets continued to do well following the end of the pandemic, CLCT's so-called "new economy" logistics assets did not. 

See also: DBS says S’pore T-bill holders are a ‘liquidity catalyst’ for S-REITs like Lendlease REIT, Keppel REIT

In her Jan 30 note, Ada Lim of OCBC Investment Research says CLCT is still seen as a beneficiary of China’s reopening and pro-growth policies in the longer term.

She believes that the recent stimulus measures by the Chinese government as potential green shoots, but expects the recovery to pan out as a multi-year story.

"We turn more conservative on our forecasts and increase our cost of equity assumption amidst a more operating challenging environment," adds Lim, who has lowered her fair value from $1.02 to 95 cents, while keeping her "buy" call.

See also: Handle duplicate Breaking news pushes

In their Jan 31 note, Geraldine Wong and Derek Tan of DBS Group Research point out that CLCT continues to experience weakness in the new economy segments and a depreciating RMB against the Singdollar.

They've lowered their target price from $1.20 to $1.05, to factor in slower negatives for CLCT's logistics segment and the divestment of Shuangjing mall, among others.

Nonetheless, with a yield of more than 8%, and with the counter trading at just 0.6x book value, they've kept their "buy" call.

 

 

Highlights

New IHH Healthcare CEO Nair lays out growth plans
Company in the news

New IHH Healthcare CEO Nair lays out growth plans

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.